A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1Rf

Detalles Bibliográficos
Autores principales: Singh, Dave, Bogus, Maxim, Moskalenko, Valentyn, Lord, Robert, Moran, Edmund J., Crater, Glenn D., Bourdet, David L., Pfeifer, Nathan D., Woo, Jacky, Kaufman, Elad, Lombardi, David A., Weng, Emily Y., Nguyen, Tuan, Woodcock, Ashley, Haumann, Brett, Saggar, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859971/
https://www.ncbi.nlm.nih.gov/pubmed/34210790
http://dx.doi.org/10.1183/13993003.00673-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859971/
https://www.ncbi.nlm.nih.gov/pubmed/34210790
http://dx.doi.org/10.1183/13993003.00673-2021

Ejemplares similares